Literature DB >> 33236263

Is impaired dopaminergic function associated with mobility capacity in older adults?

Simon Moskowitz1, David W Russ1,2,3, Leatha A Clark1,4,5, Nathan P Wages1,4, Dustin R Grooms1,6, Adam J Woods7, Julie Suhr1,8, Janet E Simon1,6, Andrew O'Shea7, Cody R Criss1, Paolo Fadda9, Brian C Clark10,11,12.   

Abstract

The capacity to move is essential for independence and declines with age. Slow movement speed, in particular, is strongly associated with negative health outcomes. Prior research on mobility (herein defined as movement slowness) and aging has largely focused on musculoskeletal mechanisms and processes. More recent work has provided growing evidence for a significant role of the nervous system in contributing to reduced mobility in older adults. In this article, we report four pieces of complementary evidence from behavioral, genetic, and neuroimaging experiments that, we believe, provide theoretical support for the assertion that the basal ganglia and its dopaminergic function are responsible, in part, for age-related reductions in mobility. We report four a posteriori findings from an existing dataset: (1) slower central activation of ballistic force development is associated with worse mobility among older adults; (2) older adults with the Val/Met intermediate catecholamine-O-methyl-transferase (COMT) genotype involved in dopamine degradation exhibit greater mobility than their homozygous counterparts; (3) there are moderate relationships between performance times from a series of lower and upper extremity tasks supporting the notion that movement speed in older adults is a trait-like attribute; and (4) there is a relationship of functional connectivity within the medial orbofrontal (mOFC) cortico-striatal network and measures of mobility, suggesting that a potential neural mechanism for impaired mobility with aging is the deterioration of the integrity of key regions within the mOFC cortico-striatal network. These findings align with recent basic and clinical science work suggesting that the basal ganglia and its dopaminergic function are mechanistically linked to age-related reductions in mobility capacity.

Entities:  

Keywords:  Aging; Basal ganglia; Dopamine; Mobility; Neural control; Sarcopenia

Year:  2020        PMID: 33236263      PMCID: PMC8190430          DOI: 10.1007/s11357-020-00303-z

Source DB:  PubMed          Journal:  Geroscience        ISSN: 2509-2723            Impact factor:   7.713


  141 in total

Review 1.  The integrative function of the basal ganglia in instrumental conditioning.

Authors:  Bernard W Balleine; Mimi Liljeholm; Sean B Ostlund
Journal:  Behav Brain Res       Date:  2008-11-05       Impact factor: 3.332

Review 2.  Pathophysiology of parkinsonism.

Authors:  Adriana Galvan; Thomas Wichmann
Journal:  Clin Neurophysiol       Date:  2008-05-07       Impact factor: 3.708

Review 3.  Imaging insights into basal ganglia function, Parkinson's disease, and dystonia.

Authors:  A Jon Stoessl; Stephane Lehericy; Antonio P Strafella
Journal:  Lancet       Date:  2014-06-18       Impact factor: 79.321

Review 4.  The basal ganglia: from motor commands to the control of vigor.

Authors:  Joshua T Dudman; John W Krakauer
Journal:  Curr Opin Neurobiol       Date:  2016-03-21       Impact factor: 6.627

Review 5.  Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors.

Authors:  P T Männistö; S Kaakkola
Journal:  Pharmacol Rev       Date:  1999-12       Impact factor: 25.468

6.  Regulation of striatal dopamine release by presynaptic auto- and heteroreceptors.

Authors:  Hui Zhang; David Sulzer
Journal:  Basal Ganglia       Date:  2012-03-01

7.  Neuroanatomical predictors of L-DOPA response in older adults with psychomotor slowing and depression: A pilot study.

Authors:  Bret R Rutherford; Jongwoo Choi; Mark Slifstein; Kaleigh O'Boyle; Anissa Abi-Dargham; Patrick J Brown; Melanie W Wall; Nora Vanegas-Arroyave; Jayant Sakhardande; Yaakov Stern; Steven P Roose
Journal:  J Affect Disord       Date:  2020-01-15       Impact factor: 4.839

8.  Sarcopenia Definition: The Position Statements of the Sarcopenia Definition and Outcomes Consortium.

Authors:  Shalender Bhasin; Thomas G Travison; Todd M Manini; Sheena Patel; Karol M Pencina; Roger A Fielding; Jay M Magaziner; Anne B Newman; Douglas P Kiel; Cyrus Cooper; Jack M Guralnik; Jane A Cauley; Hidenori Arai; Brian C Clark; Francesco Landi; Laura A Schaap; Suzette L Pereira; Daniel Rooks; Jean Woo; Linda J Woodhouse; Ellen Binder; Todd Brown; Michelle Shardell; Quian-Li Xue; Ralph B DʼAgostino; Denise Orwig; Greg Gorsicki; Rosaly Correa-De-Araujo; Peggy M Cawthon
Journal:  J Am Geriatr Soc       Date:  2020-03-09       Impact factor: 5.562

9.  Differential effects of COMT on gait and executive control in aging.

Authors:  R Holtzer; L Ozelius; X Xue; T Wang; R B Lipton; J Verghese
Journal:  Neurobiol Aging       Date:  2008-06-10       Impact factor: 4.673

10.  A dataset of multi-contrast population-averaged brain MRI atlases of a Parkinson׳s disease cohort.

Authors:  Yiming Xiao; Vladimir Fonov; M Mallar Chakravarty; Silvain Beriault; Fahd Al Subaie; Abbas Sadikot; G Bruce Pike; Gilles Bertrand; D Louis Collins
Journal:  Data Brief       Date:  2017-04-15
View more
  2 in total

1.  Sarcopenia and Neuroscience: Learning to Communicate.

Authors:  Brian C Clark; Richard G Carson
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2021-09-13       Impact factor: 6.053

2.  Heterogeneity of the strength response to progressive resistance exercise training in older adults: Contributions of muscle contractility.

Authors:  Leatha A Clark; David W Russ; Dallin Tavoian; W David Arnold; Timothy D Law; Christopher R France; Brian C Clark
Journal:  Exp Gerontol       Date:  2021-06-04       Impact factor: 4.253

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.